Product News from the May 20 MM&M News Brief

Share this article:

Product News
The FDA granted traditional approval status to GlaxoSmithKline's Trizivir (abacavir sulfate, lamivudine and zidovudine) for the treatment of HIV infection. Trizivir is the first and only FDA-approved, fixed-dose-combination drug for HIV that combines three drugs into one tablet, GSK said.

Roche has decided to discontinue the sale and distribution of its HIV medication Fortovase (saquinavir), as clinical demand for the drug has declined significantly due to the availability of a new formulation of Invirase (saquinavir mesylate). The removal of Fortovase, which will be discontinued during the first quarter of 2006, is completely voluntary and is not due to safety or efficacy issues, Roche said.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.